Copy Link Print Information

Valproic acid sodium (2:1)

(Synonyms: Sodium Valproate (2:1); VPA sodium (2:1); 2-Propylpentanoic acid sodium (2:1))
69 Cited Publications
Customer Review

Based on 69 publication(s) in Google Scholar

Valproic acid (VPA) sodium (2:1) is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium (2:1) activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium (2:1) is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches.

For research use only. We do not sell to patients.

  • CAS No.: 76584-70-8
  • Formula: C8H15O2.1/2Na
  • Molecular Weight:154.71
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Valproic acid sodium (2:1) Chemical Structure
    Valproic acid sodium (2:1) Chemical Structure
  • Experimental Validation Results for Valproic acid sodium (2:1)
  • Experimental Validation Results for Valproic acid sodium (2:1)
  • Experimental Validation Results for Valproic acid sodium (2:1)
  • Experimental Validation Results for Valproic acid sodium (2:1)
  • Experimental Validation Results for Valproic acid sodium (2:1)
  • Experimental Validation Results for Valproic acid sodium (2:1)
  • Experimental Validation Results for Valproic acid sodium (2:1)
  • Experimental Validation Results for Valproic acid sodium (2:1)
  • Experimental Validation Results for Valproic acid sodium (2:1)
  • Experimental Validation Results for Valproic acid sodium (2:1)
CAS No.: 76584-70-8
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Valproic acid sodium (2:1):

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Purity & Documentation
  • References
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Valproic acid sodium (2:1)

More
Customer Validation & Images
Cell Proliferation/Viability AssayWBRT-PCRIn Vivo Efficacy StudyHistological Imaging/Staining
  • Cell Proliferation/Viability Assay
  • In Vivo Efficacy Study
  • In Vivo Efficacy Study
  • In Vivo Efficacy Study
  • In Vivo Efficacy Study
  • Histological Imaging/Staining
  • WB
  • Cell Proliferation/Viability Assay
  • RT-PCR
  • WB

All HDAC Isoforms

More

All HIV Isoforms

More

All Endogenous Metabolite Isoforms

More
Keywords
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Valproic acid sodium (2:1) Chemical Structure
    Valproic acid sodium (2:1) Chemical Structure
    1/16
  • 1/16

    Valproic acid sodium (2:1) purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2025 Oct 14;23(1):670. [Abstract]

    Customer Validation
     Cell viability under treatment with different concentrations of VPA (0-40 mM; 24 h).

  • 1/16

    Valproic acid sodium (2:1) purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2025 Oct 14;23(1):670. [Abstract]

    Customer Validation
     Pregnant females received intraperitoneal injections of 600 mg/kg VPA or saline on gestational day 12.5. Immunohistochemical staining representative images and quantification of Iba1 and GFAP in hippocampal CA1, CA3, and DG regions.

  • 1/16

    Valproic acid sodium (2:1) purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2024 Nov;45(11):2290-2299. [Abstract]

    Customer Validation
     Schemes of generating Fsp1-Cre:R26R-loxp-tdTomato mice and drug treatment to induce in situ transdifferentiation. Fsp1-Cre mice were crossed with R26Rloxp-tdTomato mice in which the expression of tdTomato is prevented by a loxP-flanked STOP cassette. The F1 mice would have the red fluorescent protein tdTomato expressed specifically in the fibroblasts. CRFVPTM were given once a week for 6 weeks. Immunofluorescence staining of the cryosections of the hearts from Fsp1-Cre:R26R-loxp-tdTomato mice treated with vehicle (b) or CRFVPTM (c) for 6 weeks. C: CHIR99021, 14 mg/kg; R: RepSox, 8.6 mg/kg; F: Forskolin, 61.6 mg/kg; V: VPA, 250 mg/kg; T: TTNPB, 1 mg/kg and M: Rolipram, 2.5 mg/kg; P: Parnate, 2.7 mg/kg, CRFTM by oral gavage and VP by intraperitoneal injection once a week for 6 weeks in mice at about 8 weeks of age.

  • 1/16

    Valproic acid sodium (2:1) purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2024 Nov;45(11):2290-2299. [Abstract]

    Customer Validation
     Whole-heart imaging with light-sheet fluorescence microscopy after tissue clearing of the hearts from Fsp1-Cre:R26R-loxp-tdTomato mice treated with vehicle (a) or CRFVPTM (b). (C: CHIR99021, 14 mg/kg; R: RepSox, 8.6 mg/kg; F: Forskolin, 61.6 mg/kg; V: VPA, 250 mg/kg; T: TTNPB, 1 mg/kg and M: Rolipram, 2.5 mg/kg; P: Parnate, 2.7 mg/kg, CRFTM by oral gavage and VP by intraperitoneal injection once a week for 6 weeks in mice at about 8 weeks of age).

  • 1/16

    Valproic acid sodium (2:1) purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2024 Nov;45(11):2290-2299. [Abstract]

    Customer Validation
     a Schemes of obtaining PDGFRα-DreER:R26R-rox-tdTomato mice and drug treatment to induce in situ cardiac reprogramming in PDGFRα-DreER:R26R-roxtdTomato mice. PDGFRα-DreER mice were mated with R26R-rox-tdTomato mice in which the expression of tdTomato is prevented by a roxflanked STOP cassette. The expression of tdTomato in fibroblasts was turned on by tamoxifen treatment. CRFVPTM were given once a week for 6 weeks. b Body weigh change of the mice after chemical treatment. Immunofluorescence staining of the cryosections of the hearts from PDGFRα-DreER:R26R-rox-tdTomato mice treated with vehicle (c) or CRFVPTM (d) for 6 weeks. (C: CHIR99021, 14 mg/kg; R: RepSox, 8.6 mg/kg; F: Forskolin, 61.6 mg/kg; V: VPA, 250 mg/kg; T: TTNPB, 1 mg/kg and M: Rolipram, 2.5 mg/kg; P: Parnate, 2.7 mg/kg, CRFTM by oral gavage and VP by intraperitoneal injection once a week for 6 weeks in mice at about 8 weeks of age).

  • 1/16

    Valproic acid sodium (2:1) purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2024 Nov;45(11):2290-2299. [Abstract]

    Customer Validation
     Immunofluorescence staining of α-actinin in cryosections of hearts from Fsp1-Cre:R26R-loxp-tdTomato mice treated with 7 C cocktail (CRFVPTM) or cocktails by removing 1 compound from 7 C (7C-X) for 6 weeks in vivo with Fsp1-Cre:R26R-loxp-tdTomato mice. (C: CHIR99021, 14 mg/kg; R: RepSox, 8.6 mg/kg; F: Forskolin, 61.6 mg/kg; V: VPA, 250 mg/kg; T: TTNPB, 1 mg/kg and M: Rolipram, 2.5 mg/kg; P: Parnate, 2.7 mg/kg, CRFTM by oral gavage and VP by intraperitoneal injection once a week for 6 weeks in mice at about 8 weeks of age).

  • 1/16

    Valproic acid sodium (2:1) purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2023 Jul;30(7):1811-1828. [Abstract]

    Customer Validation
     Western blot analysis using indicated antibodies was performed. Lysates were prepared from control (DMSO) cells or cells treated with Trichostatin A (TSA, 5 μM), Valproic acid (VPA, 0.5 mM), or RGFP966 (10 μM) for 24 h. GAPDH served as a loading control.

  • 1/16

    Valproic acid sodium (2:1) purchased from MedChemExpress. Usage Cited in: Mil Med Res. 2020 Nov 1;7(1):52. [Abstract]

    Customer Validation
     Valproic acid (0.1 mmol/L; 0–14 days) was used. Representative microscopy images depicting the morphological changes after chemical induction were shown. Scale bars = 100 μm.

  • 1/16

    Valproic acid sodium (2:1) purchased from MedChemExpress. Usage Cited in: Mil Med Res. 2020 Nov 1;7(1):52. [Abstract]

    Customer Validation
     Valproic acid (0.1 mmol/L; 0–7 days) was used. RT-qPCR analysis of mRNA expression levels of neuron-associated genes TUJ1 and MAP2, and DA neuron-associated genes TH and NURR1 was performed during the chemical induction.

  • 1/16

    Valproic acid sodium (2:1) purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2021 Mar;42(3):470-481. [Abstract]

    Customer Validation
     Effects of Butyrate (But, 1 mM), Vpa (5 mM) and SAHA (Vor, 1 μM) on the expression of P-gp and BCRP, NF-кB p65 and phosphorylated p65 (p-p65), and IкBα and phosphorylated IкBα (p-IкBα).

  • Valproic acid sodium (2:1)